Compare DHI & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHI | WAT |
|---|---|---|
| Founded | 1978 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 33.5B |
| IPO Year | 1995 | 1996 |
| Metric | DHI | WAT |
|---|---|---|
| Price | $154.09 | $355.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 17 |
| Target Price | $166.08 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 1.9M | 812.0K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | ★ 4.27 | N/A |
| Revenue | ★ $34,250,400,000.00 | N/A |
| Revenue This Year | $0.05 | $104.66 |
| Revenue Next Year | $5.85 | $10.40 |
| P/E Ratio | $36.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $119.54 | $275.05 |
| 52 Week High | $183.62 | $414.15 |
| Indicator | DHI | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 51.49 |
| Support Level | $149.23 | $285.81 |
| Resistance Level | $160.57 | $361.22 |
| Average True Range (ATR) | 4.02 | 12.34 |
| MACD | 1.13 | -2.04 |
| Stochastic Oscillator | 93.29 | 41.87 |
D.R. Horton is the largest homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. The firm has majority ownership of Forestar Group, a publicly traded residential lot development company. D.R. Horton's headquarters are in Arlington, Texas.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.